Department of Emergency Medicine, Jackson Memorial Health System, Miami, Florida, United States of America.
Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, United States of America.
Am J Emerg Med. 2020 Oct;38(10):2160-2168. doi: 10.1016/j.ajem.2020.08.001. Epub 2020 Aug 8.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19), may result in severe complications, multiorgan dysfunction, acute respiratory failure, and death. SARS-CoV-2 is highly contagious and places healthcare workers at significant risk, especially during aerosol-generating procedures, including airway management.
This narrative review outlines the underlying respiratory pathophysiology of patients with COVID-19 and discusses approaches to airway management in the emergency department (ED) based on current literature.
Patients presenting with SARS-CoV-2 infection are at high risk for acute respiratory failure requiring airway management. Among hospitalized patients, 10-20% require intensive care unit admission, and 3-10% require intubation and mechanical ventilation. While providing respiratory support for these patients, proper infection control measures, including adherence to personal protective equipment policies, are necessary to prevent nosocomial transmission to healthcare workers. A structured approach to respiratory failure in these patients includes the use of exogenous oxygen via nasal cannula or non-rebreather, as well as titrated high-flow nasal cannula and non-invasive ventilation. This review offers several guiding principles and resources designed to be adapted in conjunction with local workplace policies for patients requiring respiratory support.
While the fundamental principles of acute respiratory failure management are similar between COVID-19 and non-COVID-19 patients, there are some notable differences, including a focus on provider safety. This review provides an approach to airway management and respiratory support in the patient with COVID-19.
引发 2019 年冠状病毒病(COVID-19)的严重急性呼吸综合征相关冠状病毒 2(SARS-CoV-2)可能导致严重并发症、多器官功能障碍、急性呼吸衰竭和死亡。SARS-CoV-2 具有高度传染性,使医护人员面临巨大风险,尤其是在进行气溶胶生成操作时,包括气道管理。
本综述概述了 COVID-19 患者的潜在呼吸病理生理学,并根据现有文献讨论了急诊科(ED)的气道管理方法。
患有 SARS-CoV-2 感染的患者有发生需要气道管理的急性呼吸衰竭的高风险。在住院患者中,10-20%需要入住重症监护病房,3-10%需要插管和机械通气。在为这些患者提供呼吸支持时,必须采取适当的感染控制措施,包括遵守个人防护装备政策,以防止医院内传播给医护人员。对这些患者的呼吸衰竭进行结构化处理包括通过鼻导管或无重复呼吸装置给予外源性氧气,以及滴定高流量鼻导管和无创通气。本综述提供了一些指导原则和资源,旨在与需要呼吸支持的患者的当地工作场所政策相结合进行调整。
虽然 COVID-19 和非 COVID-19 患者的急性呼吸衰竭管理的基本原则相似,但也存在一些明显差异,包括关注提供者的安全。本综述提供了一种针对 COVID-19 患者的气道管理和呼吸支持方法。